<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04910854</url>
  </required_header>
  <id_info>
    <org_study_id>2021HNRT02</org_study_id>
    <nct_id>NCT04910854</nct_id>
  </id_info>
  <brief_title>Surufatinib in Recurrent/Metastatic Head and Neck Adenocarcinomas</brief_title>
  <official_title>A Study of Surufatinib in the Treatment of Recurrent/Metastatic Adenocarcinomas of the Head and Neck</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a non-randomized, phase II, open label study of Surufatinib hydrochloride capsules in&#xD;
      recurrent/metastatic adenocarcinomas of head and neck. The primary purpose of this study is&#xD;
      to evaluate the efficacy of anlotinib.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>up to 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR）</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progress free survival (PFS)</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">27</enrollment>
  <condition>Head and Neck Cancers - Salivary Gland</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Surufatinib</intervention_name>
    <description>Patients receive oral Surufatinib at a dose of 300mg/d (once-daily dosing continuously, every 28-day treatment cycle), The curative effect was evaluated every 8 weeks.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provision of written Informed Consent Form (ICF) prior to any study specific&#xD;
             procedures;&#xD;
&#xD;
          2. Male and Female aged between 18 and 75 years are eligible;&#xD;
&#xD;
          3. Histologically or cytologically confirmed that recurrent or metastatic adenocarcinomas&#xD;
             of the head and neck;&#xD;
&#xD;
          4. Patients with recurrent or metastatic head and neck adenocarcinoma who are not&#xD;
             candidates for curative surgery or refusing surgical treatment;&#xD;
&#xD;
          5. Presence of at least one measurable target lesion for further evaluation according to&#xD;
             RECIST criteria;&#xD;
&#xD;
          6. Eastern Cooperative Oncology Group (ECOG) performance status 0-2;&#xD;
&#xD;
          7. Predicted survival ≥6 months;&#xD;
&#xD;
          8. Screening laboratory values must meet the following criteria (within past 14 days):&#xD;
&#xD;
               -  neutrophils ≥1.5×109/L ;&#xD;
&#xD;
               -  platelets ≥9g/dL；&#xD;
&#xD;
               -  hemoglobin ≥ 9.0 g/dL;&#xD;
&#xD;
               -  albumin≥3g/dL；&#xD;
&#xD;
               -  total bilirubin ≤ 1.5 x upper limit of normal (ULN); aspartic transaminase (AST)&#xD;
                  and alanine transaminase (ALT) ≤ 2.5 x ULN without, and ≤ 5 x ULN with hepatic&#xD;
                  metastasis; serum creatinine ≤1.5╳ULN;&#xD;
&#xD;
          9. Males or female of childbearing potential must: agree to use using a reliable form of&#xD;
             contraception (eg, oral contraceptives, intrauterine device, control sex desire,&#xD;
             double barrier method of condom and spermicidal) during the treatment period and for&#xD;
             at least 6 months after the last dose of study drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Prior treatment with Surufatinib,or other antiangiogenic drugs were used within 6&#xD;
             months; 2. Prior antitumor therapy with chemotherapy, radical radiation therapy&#xD;
             ，biological immunotherapy，targeted therapy within 4 weeks.&#xD;
&#xD;
             3. Prior participation in other clinical trials not approved or listed in China within&#xD;
             past 4 weeks； 4. Prior major surgery within past 4 weeks (diagnostic surgery&#xD;
             excluded); 5. International standardized ratio (INR) &gt;1.5 or partially activated&#xD;
             prothrombin time (APTT) &gt;1.5×ULN; 6. Clinically significant severe electrolyte&#xD;
             abnormality judged by investigator ; 7. Hypertension that is not controlled by the&#xD;
             drug, and is defined as: SBP≥140 mmHg and/or DBP≥90 mmHg; 8. Currently suffering from&#xD;
             poorly controlled diabetes (after regular treatment, fasting plasma glucose&#xD;
             concentration ≥10mmol/L); 9. The patient currently has disease or condition that&#xD;
             affects the absorption of the drug, or the patient cannot be administered orally; 10.&#xD;
             Digestive tract disease such as gastric and duodenal active ulcer, ulcerative colitis&#xD;
             or unresected tumor, or other conditions determined by the investigator that may cause&#xD;
             gastrointestinal bleeding and perforation; 11. Evidence of bleeding tendency or&#xD;
             history within 3 months, or thromboembolic event (including a stroke event and/or a&#xD;
             transient ischemic attack) occurred within 12 month; 12. Cardiovascular disease of&#xD;
             significant clinical significance (myocardial infarction, unstable arrhythmia or&#xD;
             unstable angina ，Coronary Artery Bypass Grafting within past 6 months,)； 13. Had other&#xD;
             malignant tumors in the past 5 years (except for basal cell carcinoma or squamous cell&#xD;
             carcinoma, cervical carcinoma in situ that have been effectively controlled); 14.&#xD;
             Active or uncontrolled severe infection (≥CTCAE2 infection); 15. Positive tests for&#xD;
             HIV, HCV, HBsAg or HBcAb with positive test for HBV DNA (&gt;2000IU/ml); 16. Evidence&#xD;
             with active CNS disease or previous brain metastases; 17. The toxicity associated with&#xD;
             previous anti-tumor treatment has not recovered to ≤CTCAE1, except for peripheral&#xD;
             neurotoxicity and alopecia ≤CTCAE2 caused by oxaliplatin; 18. Pregnant or nursing; 19.&#xD;
             Transfusion therapy, blood products and hematopoietic factors, such as albumin and&#xD;
             granulocyte colony stimulating factor (G-CSF), had been received within 14 days before&#xD;
             enrollment; 20. Tumor involving skin and/or pharyngeal mucosa with ulceration; 21.&#xD;
             Patients with a history of psychotropic drug abuse and unable to quit or with mental&#xD;
             disorders; 22. Any other disease, with clinical significance of metabolic&#xD;
             abnormalities, abnormal physical examination or laboratory abnormalities, according to&#xD;
             researchers, there is reason to doubt is not suitable for the use of study drugs in&#xD;
             patients with a disease or condition (such as have a seizure and require treatment),&#xD;
             or will affect the interpretation of results, or make the patients at high risk.&#xD;
&#xD;
             23. Routine urine indicated that urine protein ≥2+, and the 24-hour urine protein&#xD;
             volume &gt;1.0g; 24. Underlying medical condition that, in the Investigator's opinion,&#xD;
             would increase the risks of study drug administration or obscure the interpretation of&#xD;
             toxicity determination or adverse events.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guopei Zhu, M.D.</last_name>
      <phone>+8621 6417 5590</phone>
      <email>antica@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Guopei Zhu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 28, 2021</study_first_submitted>
  <study_first_submitted_qc>May 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 2, 2021</study_first_posted>
  <last_update_submitted>May 28, 2021</last_update_submitted>
  <last_update_submitted_qc>May 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

